North China Pharmaceutical (SHA:600812) subsidiary Xiantai Pharmaceutical received good manufacturing practice compliance approval from the Hebei drug administrator for its production lines of ampicillin sodium, amoxicillin and amoxicillin heavy powder.
The inspection was conducted from Nov. 26 to Nov. 29, 2024, according to a Monday filing with the Shanghai bourse.
Ampicillin sodium is a broad-spectrum semi-synthetic penicillin. Amoxicillin is used to treat respiratory and urinary tract infections.